A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients

Trial Profile

A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs PQ 912 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 17 Oct 2017 New trial record
    • 16 Oct 2017 According to a Probiodrug media release, Philip Scheltens will serve as the Prinacipal Investigator and Chairperson for this study. This trial is a part of the phase IIb core program starts which is planned to comprise of two complementary clinical Proof of Concept studies in Europe and the US.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top